BrainsWay Ltd. reiterated earnings guidance for the year 2023. As a reminder, the company continue to expect to demonstrate revenue growth over 2022 and are targeting breakeven operating income.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1,178 ILa | -2.00% | -1.83% | +2.52% |
Jun. 03 | Brainsway's Deep Transcranial Magnetic Stimulation Gets Expanded FDA Labeling; Shares Rise | MT |
Jun. 03 | BrainsWay Ltd. Receives Expanded FDA Labeling to Treat Late Life Depression | CI |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+2.52% | 105M | |
+9.55% | 222B | |
+14.41% | 196B | |
+24.02% | 148B | |
+33.92% | 114B | |
+4.98% | 65.69B | |
+12.92% | 51.88B | |
+3.16% | 50.02B | |
-4.32% | 38.81B | |
-1.99% | 34.59B |
- Stock Market
- Equities
- BWAY Stock
- News BrainsWay Ltd.
- BrainsWay Ltd. Reiterates Earnings Guidance for the Year 2023